Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ZSP0678 in Healthy Chinese Subjects
NCT04137055Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZSP0678 in Nonalcoholic steatohepatitis (NASH), sponsored by Raynovent Biotech. Primary endpoints: Number and severity of adverse events (AEs) and Serious Adverse Events (SAE) up to 18 days, Time to Maximum Plasma Concentration (Tmax) up to 18 days and 10 more. Started Nov 2019; status: completed.
02
Drugs
ZSP0678
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04137055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137055.